Precision medicine case study in numbers

0

Gene biomarker profile

0

Correctly identified responding patients

Background:
For a drug in development (phase II), the client had a dual goal: to understand the biology behind response or lack of response to the drug and obtain a genetic biomarker profile to separate the two groups.

Approach:
Using genetic data from patients in the phase II trial and public domain transcription data as input to our platform, Intomics did identify a biological mechanism likely related to response. Furthermore, a 12-gene biomarker profile was derived.

Performance:
The 12-gene biomarker profile was applied to new patients in the clinical trial to assess its performance. It was able to correctly classify more than 90% of the patients with respect to response or lack of response.

Outcome:
The client obtained a high-performance biomarker response profile and insight into the molecular biology underlying lack of response. The latter provided a molecular-level view of an unmet need in the disease.

Drug repositioning